z-logo
open-access-imgOpen Access
Identification of differentially expressed molecules in adult T‐cell leukemia cells proliferating in vivo
Author(s) -
Koga Hikari,
Imada Kazunori,
Ueda Maki,
Hishizawa Masakatsu,
Uchiyama Takashi
Publication year - 2004
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2004.tb03224.x
Subject(s) - syk , biology , cancer research , cd44 , leukemia , in vivo , flow cytometry , cell culture , cell growth , microbiology and biotechnology , cell , signal transduction , immunology , tyrosine kinase , genetics
HTLV‐I is the causative agent of adult T‐cell leukemia (ATL). However, the precise mechanism underlying the neoplastic cell growth of ATL remains unclear. In this study, we established a leukemic cell line, termed SYK‐11L(+), from tumor cells (S‐YU) in an in vivo cell proliferation model of ATL using severe combined immunodeficiency (SCID) mice. Unexpectedly, SYK‐11L(+) was found to have no tumorigenicity in SCID mice. Flow cytometric analysis showed that S‐YU expressed cell adhesion molecules including CD44, ICAM‐1 and OX40, whereas SYK‐11L(+) had lost the expression of these molecules. The administration of anti‐OX40 monoclonal antibody inhibited the engraftment of S‐YU cells into SCID mice, suggesting that OX40 is a potential target for immunotherapy. Significant differences in responsiveness to IL‐2 and IL‐15 were observed between the two cell types. To better understand the molecular basis of tumorigenicity, cDNA microarray analysis was performed using tumorigenic S‐YU and non‐tumori‐genic SYK‐11L(+) cells. We obtained several candidate genes differentially overexpressed in S‐YU compared with SYK‐11L(+). Interestingly, one such gene, regulator of G protein signaling 1 (RGS1), was shown to be overexpressed in most ATL patients. Further characterization of the differentially expressed molecules, such as OX40 and RGS1, would provide useful information not only to elucidate the mechanism of ATL cell growth in vivo , but also to develop novel molecularly targeted therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here